Publications by authors named "Jenifer Kogin"
Article Synopsis
- Tamoxifen metabolism is influenced by treatment adherence, co-medication, and molecular factors like the CYP2D6 genotype, impacting breast cancer prognosis.
- A study of 149 Brazilian patients on tamoxifen found that low levels of the active metabolite (Z)-endoxifen at 3 months may correlate with shorter event-free survival (EFS).
- However, results were inconsistent; while some analyses suggested an association, others did not, indicating a need for larger studies to explore the link between tamoxifen metabolism and breast cancer recurrence.
Tamoxifen efficacy in breast cancer is suspected to depend on adherence and intact drug metabolism. We evaluated the role of adherence behavior and pharmacogenetics on the formation rate of (Z)-endoxifen. In 192 Brazilian patients, we assessed plasma levels of tamoxifen and its metabolites at 3, 6, and 12 months of treatment (liquid-chromatography tandem mass spectrometry), adherence behavior (Morisky, Green, and Levine medication adherence scale), and cytochrome P450 2D6 (CYP2D6) and other pharmacogene polymorphisms (matrix-assisted laser-desorption-ionization time of flight) mass spectrometry, real-time polymerase chain reaction).
View Article and Find Full Text PDF